SCHEMBL16183248

SCHEMBL16183248

CNc1nc(-c2ccccn2)nc2ccc(-c3ccc(F)c(F)c3)c(F)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP1 P53582 3/20 0.43
▸ METAP2 P50579 2/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ RAB9A P51151 4/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ FFAR1 O14842 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ TOP1 P11387 1/20 0.38
▸ FEN1 P39748 2/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ NPC1 O15118 2/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183250 0.87 GRM5 (0.44) METAP1METAP2KDM4ELMNAHTT
SCHEMBL14474742 0.86 FEN1 (0.43) RAB9AFEN1NPC1TGFBR1
SCHEMBL16183246 0.86 METAP1 (0.45) METAP1METAP2KDM4ELMNAHTT
SCHEMBL16184295 0.81 CYP1A2 (0.50) KDM4ELMNARAB9AMAPK1ALDH1A1
SCHEMBL14474140 0.79 LMNA (0.45) METAP1METAP2KDM4ELMNAHTT
SCHEMBL16184334 0.78 FEN1 (0.41) RAB9AFEN1NPC1
SCHEMBL16184330 0.78 NPC1 (0.41) RAB9AFEN1NPC1
SCHEMBL16184319 0.76 MAP4K4 (0.44) RAB9AFEN1NPC1TGFBR1
SCHEMBL16184323 0.76 MAP4K4 (0.41) METAP1METAP2RAB9AMAPTMEN1
SCHEMBL16184318 0.75 NPC1 (0.41) KDM4EHTTSMN1; SMN2RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB METAP1 1661/4885METAP2 2043/4885KDM4E 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback